Astra Zeneca and Merck partner on drug regimen
AstraZeneca and Merck & Co. have formed an alliance to research the combination of two investigational compounds: AZD6244 (ARRY-886) from AstraZeneca and MK-2206 from Merck. They will work together on a phase I trial and share the costs of the research.
AstraZeneca and Merck & Co. have formed an alliance to research the combination of two investigational compounds: AZD6244 (ARRY-886) from AstraZeneca and MK-2206 from Merck. They will work together on a phase I trial and share the costs of the research.
AZD6244 blocks the MEK pathway and is currently under investigation in skin, colorectal, and lung cancers. MK-2206 is an AKT pathway inhibitor that has shown promise in phase I testing in advanced solid tumors (ASCO 2009 abstract 3503).
Articles in this issue
Letrozole appears less detrimental than tamoxifen to cognitive function in breast ca
Accelerated whole-breast irradiation does more with less after lumpectomy
RIBBON-1 results bolster bevacizumab as add-on to standard Rx for metastatic breast cancer
PET/CT Indicates if Early Neoadjuvant Rx is Making the Grade in Sarcoma Patients
Less is more when it comes to serial CA125 testing in ovarian cancer
Treatment varies widely in chronic myeloid leukemia
Should expectant management serve as the primary treatment option in prostate cancer?
Oncology takes blame for rising healthcare cost
Healthcare advocates call for universal coverage, acknowledge challenges
NSABP chair admits ‘failure’ in C-08 trial, denies defeat
Gemcitabine, capecitabine regimens equal in breast ca mets
Study ties survival to inflammatory markers in breast cancer
Canadians rally for national standards for breast ca testing
Trio of genes plays role in breast ca mets to brain
Micromet BiTE antibody eliminates leukemia cells
Recent Videos
Related Content
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
